Real-World Study

FIRE study design

The FIRE study was a multicentre, retrospective and prospective non-interventional study assessing IMBRUVICA^® outcomes of CLL patients aged ≥18 years.^[1]

Median age^[1]

72 years
(N = 394)

Prior therapies^[1]

85%
≥1 prior therapy
(N = 394)

Patients were either treatment-naïve with del(17p) and/or TP53 mutation, or relapsed/refractory.^[1]

Primary endpoint^[1]

PFS

Secondary endpoint^[1]

OS and ORR

CLL patient subgroups

uIGHV patients

Genetic aberration patients

Fit patients

Relapsed / refractory patients

Back to IMBRUVICA^® studies

CLL=chronic lymphocytic leukaemia; ORR=overall response rate; OS=overall survival; PFS=progression-free survival; R/R=relapsed/refractory.

CP-352641 - CP-352642 - October 2022

FIRE study design

Median age[1]

72 years(N = 394)

Prior therapies[1]

85%≥1 prior therapy(N = 394)

Patients were either treatment-naïve with del(17p) and/or TP53 mutation, or relapsed/refractory.[1]

Primary endpoint[1]

PFS

Secondary endpoint[1]